These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Reginster JY Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506 [TBL] [Abstract][Full Text] [Related]
11. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Miller PD Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811 [TBL] [Abstract][Full Text] [Related]
12. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Emkey RD; Ettinger M Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937 [TBL] [Abstract][Full Text] [Related]
13. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance. Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505 [TBL] [Abstract][Full Text] [Related]
14. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Lewiecki EM; Babbitt AM; Piziak VK; Ozturk ZE; Bone HG Clin Ther; 2008 Apr; 30(4):605-21. PubMed ID: 18498910 [TBL] [Abstract][Full Text] [Related]
15. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. Chesnut CH Drugs; 2006; 66(10):1351-9. PubMed ID: 16903769 [TBL] [Abstract][Full Text] [Related]
16. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. Reginster JY Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890 [TBL] [Abstract][Full Text] [Related]
17. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens. Epstein S Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003 [TBL] [Abstract][Full Text] [Related]
19. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Gold DT; Safi W; Trinh H Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452 [TBL] [Abstract][Full Text] [Related]
20. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis]. Reginster JY Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]